Skip to main content
. 2019 Apr 29;3(9):1368–1378. doi: 10.1182/bloodadvances.2017007914

Figure 5.

Figure 5.

In vitro efficacy of pFVIII-expressing iMKs in ROTEM studies. ROTEM studies, as in Figure 1, but with added hBDFVIII (BD), hBDFVIIIRH (RH), or nontransfected control (NTC) iMKs instead of line h38 platelets. Each curve represents 5 independent studies. (A) Addition of 5 × 103 iMKs to 110 µL of whole blood from FVIIInull (KO) mice. WT and FVIIInull mice blood were studied as positive and negative controls, respectively. (B) Same as in panel A, with 5 × 104 BD or RH iMKs. (C) Same as in panel A, but with (dotted lines) or without (solid lines) 10 nM of rFVIIa added. Arrows indicate paired studies with or without rFVIIa. Supplemental Table 4 and supplemental Table 5 summarize parametric analyses of these data for Figure 6A-B and Figure 6C, respectively.